Ribavirin

Product Description

Ribavirin is an antiviral guanosine ribonucleoside analog; misincorporated into mRNA by viral-dependent RNA polymerases. Binds to and redistributes mammalian eIF4E from the nucleus to the cytoplasm (K_i ~ 0.3 μM for the active metabolite, ribavirin triphosphate). Also inosine monophosphate dehydrogenase (IMPDH) inhibitor. Represses colony formation of primary AML-M5 progenitor cells (IC₅₀ ~ 1 μM); reduces disease severity in acute myeloid leukemia (AML). Inhibits cytopathic effect of SARS-CoV in Vero cells in vitro. Orally available.

Solubility

Preparing Stock Solutions for Ribavirin

The following data is based on the product molecular weight 244.20

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.10 mL	20.48 mL	40.95 mL
5 mM	0.82 mL	4.10 mL	8.19 mL
10 mM	0.41 mL	2.05 mL	4.10 mL
50 mM	0.08 mL	0.41 mL	0.82 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Graci and Cameron Mechanisms of action of ribavirin against distinct viruses. Rev.Med.Virol. 2006 PMID: 16287208
• Assouline Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with riba. Blood 2009 PMID: 19433856
• Tan Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg.Infect.Dis. 2004 PMID: 15200845
• Kentsis Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc.Natl.Acad.Sci.U.S.A. 2004 PMID: 15601771